<DOC>
	<DOCNO>NCT02608853</DOCNO>
	<brief_summary>This study conduct United States America . The aim study estimate incidence rate malignant neoplasm , specific subgroup malignant neoplasm , acute pancreatitis among cohort antidiabetic drug user standardize representative LEADER™ trial participant liraglutide initiator within Humedica Electronic Health Record ( EHR ) database .</brief_summary>
	<brief_title>Estimation Malignancy Rates Within Humedica Patient Populations Sampled Representative Liraglutide Initiators LEADER™ Trial Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>All Cohort Members : Members cohort must least 12 month baseline coverage within Humedica prior patient ' index date ( cohort specific index date define ) . Within Humedica , baseline coverage define date early observed encounter include index date . Patients must least 1 diagnosis T2DM ( 250.X0 250.X2 ) prior include date qualifying prescription , prior diagnosis ( inclusive index date ) T1DM ( 250.X1 250.X3 ) diagnosis gestational diabetes within previous 12 month ( inclusive index date ) . Patients eligible inclusion prior prescription GLP1 analogue ( include liraglutide exenatide ) interval would consider baseline period Liraglutidelike Cohort : To eligible inclusion Liraglutidelike Cohort , patient must least one qualify prescription OAD . Qualifying OADs specify share similar label unlabelled indication liraglutide LEADER™like Cohort : To eligible inclusion LEADERTMlike Cohort , patient must meet following inclusion exclusion criterion : Patients eligible inclusion meeting overall inclusion exclusion criterion addition follow : Ages 50 . HbA1c least 7 % Patients exclude LEADER™like Cohort follow observe prior meeting inclusion criterion define : Calcitonin &gt; = 50ng/L . Baseline DPP4 pramlintide . Chronic heart failure diagnosis , NYHA Class IV . Acute coronary cerebrovascular event within 14 day prior initiation . Current continuous renal replacement therapy . Endstage liver disease . Solid organ transplant . Malignant neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>